RELEX-SOLUTIONS
Today, RELEX Solutions, provider of unified supply chain and retail planning solutions, announced it has acquired Optimity, a supply chain planning and optimization provider. The acquisition will bolster the RELEX retail and supply chain platform with daily production planning, optimization and production scheduling capabilities which are crucial for the end-to-end consumer goods value chain.
“The consumer goods industry is incredibly dynamic and complex. Acquiring Optimity will seamlessly link downstream demand with upstream planning, so consumer goods companies can more accurately predict consumer demand, optimize production plans and schedules, adjust inventory levels, and respond quickly to market changes or unexpected disruptions,” said Mikko Kärkkäinen, co-founder and group CEO, RELEX. “This acquisition also further accelerates our vision towards an adaptive, autonomous and synchronized supply chain unifying demand and supply planning decisions in one platform to minimize all wasted cost and product. We warmly welcome the Optimity team to RELEX.”
Optimity, with global headquarters in Sweden and offices around the world, offers a broad supply chain planning and optimization solution specifically for manufacturers and distributors. Optimity enables customers to make optimal supply chain decisions from strategic levels to detailed production scheduling. Their offerings include demand planning, production planning and scheduling, supply planning, distribution planning, inventory optimization, and S&OP. With 80+ customers across the food and beverage, and complex manufacturing industries, Optimity’s experience augments RELEX’s expertise across retail and consumer goods markets.
The acquisition brings together a highly complementary offering between the two organizations, enabling RELEX to extend and deepen its production planning and supply chain optimization capabilities, such as synchronized daily production planning, optimization and scheduling in the food & beverage and manufacturing sector.
New or expanded capabilities within the RELEX unified retail and supply chain planning platform from Optimity include:
- Production planning: Create optimized production plans from up-to-date forecasts to balance operational costs and flexibility while considering production restrictions, material constraints and business priorities.
- Production scheduling: Generate and manage optimized production schedules built around constraints to reduce changeover time and bolster manufacturing efficiency.
- Network balancing: Rectify imbalances in complex distribution networks to minimize risks, reduce costs, and boost operational efficiency.
- Distribution planning: Gain complete distribution network visibility to make smarter, proactive decisions aligned with business objectives and customer service goals.
- Purchase planning: Balance supply-side complexity with end-to-end visibility to pinpoint the most efficient and profitable way to fulfill demand plans and customer obligations.
“Our depth in some of the most complex consumer goods industries like bakery, ready-made meals, protein production and industrial manufacturing complements the vast understanding of consumer demand that RELEX has, based on their impressive expertise managing more than $700 billion of demand in grocery alone,” said Christer Liden, CEO, Optimity. “We are thrilled to join the RELEX team and further optimize the consumer goods value chain together.”
To learn more about the acquisition, please visit this page.
About RELEX
RELEX Solutions helps retailers and consumer brands drive profitable growth across all sales and distribution channels by maximizing customer satisfaction and minimizing operative costs. Our market-leading, unified supply chain and retail planning platform helps retailers and consumer goods companies align and optimize demand, merchandising, supply chain, and operations planning across the end-to-end value chain. We drive record-high product availability, increased sales, improved sustainability, and the best return on investment in inventory, space, workforce, and capacity. Leading brands like Dollar Tree and Family Dollar, Stokke, Rite Aid, Sprouts Farmers Market, AutoZone, and PetSmart trust RELEX to optimize their supply chain and retail planning. Go to relexsolutions.com for more.
About Optimity
For nearly two decades, Optimity has challenged the supply chain planning space. Optimity has provided companies with user-friendly yet powerful planning software to optimize even the most intricate supply chains. We believe every supply chain can maximize profits effortlessly with the right tools. Optimity delivers a comprehensive solution, covering strategic optimization to detailed production scheduling. Our expert team, boasting years of industry knowledge, ensures success in every project. Supply chain planning is pivotal for manufacturing and distribution, and Optimity excels in delivering solid solutions for complex supply chains. Our integrated planning tool ensures profitability, simplifying processes for sustainable growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103171132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom